No Data
No Data
Gilead To Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline And HIV Leadership At IDWeek 2024
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Express News | Nurix Therapeutics Will Present Preclinical Data From NX-5948, Currently In Phase 1b For B-Cell Malignancies And In IND-Enabling Studies For Autoimmune Disease, And GS-6791/NX-0479 In Collaboration With Gilead Sciences And Also In IND-enabling...
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating, Announces Target Price $100
Analysts Offer Insights on Healthcare Companies: Accolade (ACCD) and Gilead Sciences (GILD)
Express News | Gilead : JP Morgan Raises Target Price to $100 From $95
No Data
No Data